The financials
Lilly (Eli) by the numbers
Lilly (Eli) (LLY) reported revenue of $23.0B in Q2 2026 (quarter ended June 30, 2026), up 48% from the same quarter a year earlier. That came with a gross margin of 86% and net income of $7.09B (31% of revenue). For the full year FY2025, revenue was $65.2B (+45% year on year) and net income $20.6B. Its largest product in 2026-Q2 was Cardiometabolic Health at $11.7B, 47% of the disclosed total, just ahead of Mounjaro at 19%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $23.0B | $15.6B | +48% |
| Gross profit | $19.7B | $13.1B | +50% |
| Net income | $7.09B | $5.66B | +25% |
| Diluted EPS | $7.94 | $6.29 | +26% |
| Product | Revenue | Share |
|---|---|---|
| Cardiometabolic Health | $11.7B | 47% |
| Mounjaro | $4.79B | 19% |
| Collaborationand Other | $1.57B | 6.3% |
| Oncology | $1.47B | 5.9% |
| Trulicity | $908M | 3.6% |
| Verzenio | $845M | 3.4% |
| Immunology | $790M | 3.1% |
| Other Oncology | $628M | 2.5% |
| Jardiance | $616M | 2.5% |
| Other Cardiometabolic Health | $554M | 2.2% |
| Taltz | $539M | 2.1% |
| Neuroscience | $325M | 1.3% |
| Other Immunology | $251M | 1.0% |
| Product And Service Other | $84M | 0.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $25.12B (+19%)
Collaboration and Other grew +89% year on yearVerzenio -9.0% year on year
Segment Latestquarter on quarteryear on year
- Cardiometabolic Health$11.74B$11.74BQoQ +18%year on year +40%+18%+40%
- Mounjaro$4.79B$4.79BQoQ +13%year on year +45%+13%+45%
- Collaboration and Other$1.57B$1.57BQoQ +17%year on year +89%+17%+89%
- Oncology$1.47B$1.47BQoQ +20%year on year +3.8%+20%+3.8%
- Trulicity$908.0M$908.0MQoQ +51%year on year +22%+51%+22%
- Verzenio$845.0M$845.0MQoQ +20%year on year -9.0%+20%-9.0%
- Immunology$790.0M$790.0MQoQ +28%year on year +13%+28%+13%
- Other Oncology$628.0M$628.0MQoQ +20%year on year +28%+20%+28%
- Jardiance$616.0M$616.0MQoQ +20%year on year +61%+20%+61%
- Other Cardiometabolic Health$554.0M$554.0MQoQ +24%year on year -0.36%+24%-0.36%
- Taltz$539.0M$539.0MQoQ +29%year on year -1.8%+29%-1.8%
- Neuroscience$325.0M$325.0MQoQ +11%year on year +31%+11%+31%
- Other Immunology$251.0M$251.0MQoQ +24%year on year +65%+24%+65%
- Product And Service Other$84.0M$84.0MQoQ +50%year on year +1.2%+50%+1.2%
- Other Product Total--QoQ -year on year ---
Drug Manufacturers - General
Ranks #1 of 16 by Smart Score